Cargando…

Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients

BACKGROUND: Osteoprotegerin (OPG) is a glycoprotein that plays an important regulatory role in the skeletal, vascular, and immune system. It has been shown that OPG predicts chronic kidney disease (CKD) in diabetic patients. We hypothesized that OPG could be a risk marker of CKD development also in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bernardi, Stella, Toffoli, Barbara, Bossi, Fleur, Candido, Riccardo, Stenner, Elisabetta, Carretta, Renzo, Barbone, Fabio, Fabris, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500921/
https://www.ncbi.nlm.nih.gov/pubmed/28683789
http://dx.doi.org/10.1186/s12882-017-0625-3
_version_ 1783248714514563072
author Bernardi, Stella
Toffoli, Barbara
Bossi, Fleur
Candido, Riccardo
Stenner, Elisabetta
Carretta, Renzo
Barbone, Fabio
Fabris, Bruno
author_facet Bernardi, Stella
Toffoli, Barbara
Bossi, Fleur
Candido, Riccardo
Stenner, Elisabetta
Carretta, Renzo
Barbone, Fabio
Fabris, Bruno
author_sort Bernardi, Stella
collection PubMed
description BACKGROUND: Osteoprotegerin (OPG) is a glycoprotein that plays an important regulatory role in the skeletal, vascular, and immune system. It has been shown that OPG predicts chronic kidney disease (CKD) in diabetic patients. We hypothesized that OPG could be a risk marker of CKD development also in non-diabetic hypertensive patients. METHODS: A case-control study was carried out to measure circulating OPG levels in 42 hypertensive patients with CKD and in 141 hypertensive patients without CKD. A potential relationship between OPG and the presence of CKD was investigated and a receiver-operating characteristic (ROC) curve was designed thereafter to identify a cut-off value of OPG that best explained the presence of CKD. Secondly, to evaluate whether OPG increase could affect the kidney, 18 C57BL/6J mice were randomized to be treated with saline or recombinant OPG every 3 weeks for 12 weeks. RESULTS: Circulating OPG levels were significantly higher in hypertensive patients with CKD, and there was a significant inverse association between OPG and renal function, that was independent from other variables. ROC analysis showed that OPG levels had a high statistically predictive value on CKD in hypertensive patients, which was greater than that of hypertension. The OPG best cut-off value associated with CKD was 1109.19 ng/L. In the experimental study, OPG delivery significantly increased the gene expression of pro-inflammatory and pro-fibrotic mediators, as well as the glomerular nitrosylation of proteins. CONCLUSIONS: This study shows that OPG is associated with CKD in hypertensive patients, where it might have a higher predictive value than that of hypertension for CKD development. Secondly, we found that OPG delivery significantly increased the expression of molecular pathways involved in kidney damage. Further longitudinal studies are needed not only to evaluate whether OPG predicts CKD development but also to clarify whether OPG should be considered a risk factor for CKD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0625-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5500921
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55009212017-07-10 Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients Bernardi, Stella Toffoli, Barbara Bossi, Fleur Candido, Riccardo Stenner, Elisabetta Carretta, Renzo Barbone, Fabio Fabris, Bruno BMC Nephrol Research Article BACKGROUND: Osteoprotegerin (OPG) is a glycoprotein that plays an important regulatory role in the skeletal, vascular, and immune system. It has been shown that OPG predicts chronic kidney disease (CKD) in diabetic patients. We hypothesized that OPG could be a risk marker of CKD development also in non-diabetic hypertensive patients. METHODS: A case-control study was carried out to measure circulating OPG levels in 42 hypertensive patients with CKD and in 141 hypertensive patients without CKD. A potential relationship between OPG and the presence of CKD was investigated and a receiver-operating characteristic (ROC) curve was designed thereafter to identify a cut-off value of OPG that best explained the presence of CKD. Secondly, to evaluate whether OPG increase could affect the kidney, 18 C57BL/6J mice were randomized to be treated with saline or recombinant OPG every 3 weeks for 12 weeks. RESULTS: Circulating OPG levels were significantly higher in hypertensive patients with CKD, and there was a significant inverse association between OPG and renal function, that was independent from other variables. ROC analysis showed that OPG levels had a high statistically predictive value on CKD in hypertensive patients, which was greater than that of hypertension. The OPG best cut-off value associated with CKD was 1109.19 ng/L. In the experimental study, OPG delivery significantly increased the gene expression of pro-inflammatory and pro-fibrotic mediators, as well as the glomerular nitrosylation of proteins. CONCLUSIONS: This study shows that OPG is associated with CKD in hypertensive patients, where it might have a higher predictive value than that of hypertension for CKD development. Secondly, we found that OPG delivery significantly increased the expression of molecular pathways involved in kidney damage. Further longitudinal studies are needed not only to evaluate whether OPG predicts CKD development but also to clarify whether OPG should be considered a risk factor for CKD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-017-0625-3) contains supplementary material, which is available to authorized users. BioMed Central 2017-07-06 /pmc/articles/PMC5500921/ /pubmed/28683789 http://dx.doi.org/10.1186/s12882-017-0625-3 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bernardi, Stella
Toffoli, Barbara
Bossi, Fleur
Candido, Riccardo
Stenner, Elisabetta
Carretta, Renzo
Barbone, Fabio
Fabris, Bruno
Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
title Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
title_full Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
title_fullStr Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
title_full_unstemmed Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
title_short Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
title_sort circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500921/
https://www.ncbi.nlm.nih.gov/pubmed/28683789
http://dx.doi.org/10.1186/s12882-017-0625-3
work_keys_str_mv AT bernardistella circulatingosteoprotegerinisassociatedwithchronickidneydiseaseinhypertensivepatients
AT toffolibarbara circulatingosteoprotegerinisassociatedwithchronickidneydiseaseinhypertensivepatients
AT bossifleur circulatingosteoprotegerinisassociatedwithchronickidneydiseaseinhypertensivepatients
AT candidoriccardo circulatingosteoprotegerinisassociatedwithchronickidneydiseaseinhypertensivepatients
AT stennerelisabetta circulatingosteoprotegerinisassociatedwithchronickidneydiseaseinhypertensivepatients
AT carrettarenzo circulatingosteoprotegerinisassociatedwithchronickidneydiseaseinhypertensivepatients
AT barbonefabio circulatingosteoprotegerinisassociatedwithchronickidneydiseaseinhypertensivepatients
AT fabrisbruno circulatingosteoprotegerinisassociatedwithchronickidneydiseaseinhypertensivepatients